PT2286825T - Ligandos do recetor de melanocortina - Google Patents

Ligandos do recetor de melanocortina

Info

Publication number
PT2286825T
PT2286825T PT101825669T PT10182566T PT2286825T PT 2286825 T PT2286825 T PT 2286825T PT 101825669 T PT101825669 T PT 101825669T PT 10182566 T PT10182566 T PT 10182566T PT 2286825 T PT2286825 T PT 2286825T
Authority
PT
Portugal
Prior art keywords
receptor ligands
melanocortin receptor
melanocortin
ligands
receptor
Prior art date
Application number
PT101825669T
Other languages
English (en)
Inventor
Xin Dong Zheng
Moreau Jacques-Pierre
Original Assignee
Ipsen Pharma Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Pharma Sas filed Critical Ipsen Pharma Sas
Publication of PT2286825T publication Critical patent/PT2286825T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
PT101825669T 2005-07-08 2006-07-10 Ligandos do recetor de melanocortina PT2286825T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69777905P 2005-07-08 2005-07-08
US74885005P 2005-12-09 2005-12-09

Publications (1)

Publication Number Publication Date
PT2286825T true PT2286825T (pt) 2017-01-02

Family

ID=37637790

Family Applications (4)

Application Number Title Priority Date Filing Date
PT10170694T PT2236151E (pt) 2005-07-08 2006-07-10 Ligandos do receptor de melanocortina
PT121887848T PT2548568T (pt) 2005-07-08 2006-07-10 Ligandos do recetor de melanocortina
PT172028367T PT3354273T (pt) 2005-07-08 2006-07-10 Ligandos do recetor de melanocortina
PT101825669T PT2286825T (pt) 2005-07-08 2006-07-10 Ligandos do recetor de melanocortina

Family Applications Before (3)

Application Number Title Priority Date Filing Date
PT10170694T PT2236151E (pt) 2005-07-08 2006-07-10 Ligandos do receptor de melanocortina
PT121887848T PT2548568T (pt) 2005-07-08 2006-07-10 Ligandos do recetor de melanocortina
PT172028367T PT3354273T (pt) 2005-07-08 2006-07-10 Ligandos do recetor de melanocortina

Country Status (21)

Country Link
US (8) US8039435B2 (pt)
EP (6) EP2236151B1 (pt)
JP (4) JP4734411B2 (pt)
KR (2) KR101232201B1 (pt)
CN (4) CN101257916B (pt)
AU (2) AU2006269261B2 (pt)
CA (4) CA2793119C (pt)
DK (4) DK2236151T3 (pt)
ES (4) ES2386862T3 (pt)
FR (1) FR21C1060I2 (pt)
HK (2) HK1149190A1 (pt)
HU (4) HUE055154T2 (pt)
IL (3) IL188545A (pt)
NL (1) NL301150I2 (pt)
NZ (2) NZ580806A (pt)
PL (4) PL2236151T3 (pt)
PT (4) PT2236151E (pt)
RU (2) RU2380372C2 (pt)
SG (1) SG163585A1 (pt)
SI (1) SI3354273T1 (pt)
WO (1) WO2007008704A2 (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007020152A1 (de) * 2007-04-26 2008-10-30 Charité - Universitätsmedizin Berlin Mittel zur antiinfektiven Behandlung eines Patienten
WO2008147556A2 (en) * 2007-05-25 2008-12-04 Ipsen Pharma S.A.S. Melanocortin receptor ligands modified with hydantoin
TW200848424A (en) * 2007-06-15 2008-12-16 Sod Conseils Rech Applic Cyclic peptide melanocortin receptor ligands
RU2453328C2 (ru) 2007-11-05 2012-06-20 Ипсен Фарма С.А.С. Применение меланокортинов для лечения чувствительности к инсулину
CN102143970B (zh) 2008-05-27 2017-02-08 健赞股份有限公司 α‑促黑素细胞激素的肽类似物
WO2009152079A1 (en) 2008-06-09 2009-12-17 Palatin Technologies, Inc. Melanocortin receptor-specific peptides for treatment of sexual dysfunction
UY32690A (es) 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
WO2010144341A2 (en) 2009-06-08 2010-12-16 Palatin Technologies, Inc. Lactam-bridged melanocortin receptor-specific peptides
EA020959B1 (ru) 2009-06-08 2015-03-31 Палатин Текнолоджиз, Инк. Пептиды, специфичные к меланокортиновым рецепторам
KR20120059520A (ko) * 2009-08-05 2012-06-08 입센 파마 에스.에이.에스 이상지질혈증을 치료하기 위한 멜라노코르틴의 용도
WO2011026015A2 (en) * 2009-08-31 2011-03-03 Gruber Kenneth A Stabilized melanocortin ligands
CN102665401A (zh) * 2009-11-16 2012-09-12 益普生制药股份有限公司 黑皮质素受体配体的药物组合物
US20120226018A1 (en) * 2009-11-16 2012-09-06 Ipsen Pharma, S.A.S. Process for the Synthesis of Ac-Arg-Cyclo(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2
NZ599774A (en) 2009-11-23 2014-11-28 Palatin Technologies Inc Melanocortin-1 receptor-specific cyclic peptides
CA2781405A1 (en) 2009-11-23 2011-05-26 Palatin Technologies, Inc. Melanocortin-1 receptor-specific linear peptides
BR112013027222B1 (pt) 2011-06-14 2022-07-12 Ipsen Pharma S.A.S. Composição de liberação sustentada que contém peptídeos como ingrediente ativo
HUE056948T2 (hu) 2011-12-29 2022-04-28 Rhythm Pharmaceuticals Inc Melanokortin-4 receptorral összefüggõ rendellenességek kezelési módszere heterozigóta hordozókban
EP2705835A1 (en) 2012-06-08 2014-03-12 Ipsen Pharma S.A.S. Aqueous gelling compositions of soluble active pharmaceutical peptides providing modified release
DK2722340T3 (en) * 2012-10-19 2015-06-08 Txp Pharma Gmbh Alpha- and gamma-MSH analogues
EP2968475A2 (en) 2013-03-14 2016-01-20 Questcor Pharmaceuticals, Inc. Acth for treatment of acute respiratory distress syndrome
JP6622690B2 (ja) 2013-03-15 2019-12-18 リズム・ファーマシューティカルズ・インコーポレイテッド ペプチド組成物
PT2970389T (pt) * 2013-03-15 2020-10-21 Rhythm Pharmaceuticals Inc Composições farmacêuticas
BR112016024494B1 (pt) 2014-04-22 2024-02-06 Txp Pharma Gmbh Análogo de peptídeo e seu uso
JP7051106B2 (ja) 2015-09-30 2022-04-11 リズム ファーマシューティカルズ， インコーポレイテッド メラノコルチン－４受容体経路関連障害の治療方法
WO2017066754A1 (en) * 2015-10-15 2017-04-20 The Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for the treatment of depression and anxiety
WO2018074999A1 (en) * 2016-10-17 2018-04-26 The Arizona Board Of Regents On Behalf Of The University Of Arizona Novel modulators of melanocortin receptors for the treatment of depression and anxiety
US11542302B2 (en) 2015-10-15 2023-01-03 Arizona Board Of Regents On Behalf Of The University Of Arizona Modulators of melanocortin receptors for the treatment of depression and anxiety
EP3596107A1 (en) * 2017-03-15 2020-01-22 Novo Nordisk A/S Bicyclic compounds capable of binding to melanocortin 4 receptor
AU2019249255A1 (en) 2018-04-06 2020-11-05 Alastair GARFIELD Compositions for treating kidney disease
US20210221867A1 (en) * 2018-05-15 2021-07-22 Novo Nordisk A/S Compounds Capable of Binding to Melanocortin 4 Receptor
CA3100868A1 (en) * 2018-05-23 2019-11-28 Provincial Health Services Authority Radiolabeled melanocortin 1 receptor-specific alpha-melanocyte-stimulating hormone analogues for imaging or therapy
US11396535B2 (en) 2019-03-01 2022-07-26 Provincial Health Services Authority Cyclic peptide analogs of melanocortin and amanitin and methods of making such
WO2022067086A1 (en) * 2020-09-24 2022-03-31 Rhythm Pharmaceuticals, Inc. Methods of treating melanocortin-4 receptor pathway-associated disorders
WO2022251650A1 (en) * 2021-05-27 2022-12-01 The Regents Of The University Of Michigan Mc3r agonist peptides
WO2024083843A1 (en) 2022-10-18 2024-04-25 Confo Therapeutics N.V. Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US613874A (en) 1898-11-08 George e
US1613874A (en) 1922-03-29 1927-01-11 Miner Inc W H Friction draft gear
US5652214A (en) 1989-06-05 1997-07-29 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
US5672659A (en) 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5595760A (en) 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
US5665702A (en) 1995-06-06 1997-09-09 Biomeasure Incorporated Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides
US5916883A (en) 1996-11-01 1999-06-29 Poly-Med, Inc. Acylated cyclodextrin derivatives
SE9700620D0 (sv) 1997-02-21 1997-02-21 Wapharm Ab Cykliska peptider med selektivitet för MSH-receptor subtyper
AU7464998A (en) 1997-10-27 1999-05-17 Trega Biosciences, Inc. Melanocortin receptor ligands and methods of using same
US6127381A (en) 1998-04-28 2000-10-03 Basu; Amaresh Isoquinoline compound melanocortin receptor ligands and methods of using same
AU758179B2 (en) * 1998-07-27 2003-03-20 Iowa State University Research Foundation Inc. Melanocortin-4 receptor gene and use as a genetic marker for fat content, weight gain, and/or feed consumption of animals
CA2341903A1 (en) 1998-08-21 2000-03-02 The Children's Medical Center Corporation Use of melanin for inhibition of angiogenesis and macular degeneration
US6716810B1 (en) 1998-12-09 2004-04-06 Eleanor Roosevelt Institute Composition and method for regulation of body weight and associated conditions
US6603058B1 (en) 1998-12-09 2003-08-05 Oklahoma Medical Research Foundation Non-human animal model for obesity and uses thereof
HUP0202203A3 (en) 1999-03-29 2003-09-29 Procter & Gamble Melanocortin receptor ligands, pharmaceutical compositions comprising thereof and method for their preparation
US6579968B1 (en) * 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction
US7176279B2 (en) * 2000-06-28 2007-02-13 Palatin Technologies, Inc. Cyclic peptide compositions and methods for treatment of sexual dysfunction
DE60040413D1 (de) 1999-11-12 2008-11-13 Merck & Co Inc Zellen mit defizientem melanocortin-3-rezeptor, transgene mäuse und verfahren zur auswahl von substanzen, die das körpergewicht regulieren können
US6600015B2 (en) 2000-04-04 2003-07-29 Hoffmann-La Roche Inc. Selective linear peptides with melanocortin-4 receptor (MC4-R) agonist activity
BR0111567A (pt) * 2000-06-28 2003-05-06 Pfizer Prod Inc Ligandos do receptor de melanocortina
US6720324B2 (en) 2000-07-05 2004-04-13 Synaptic Pharmaceutical Corporation Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof
EP1322954A4 (en) 2000-09-13 2005-08-03 Eleanor Roosevelt Inst METHOD FOR TREATING INSULIN RESISTANCE IN OVERWEIGHT AND DIABETES
US20030113263A1 (en) 2001-02-13 2003-06-19 Oregon Health And Sciences University, A Non-Profit Organization Methods and reagents for using mammalian melanocortin receptor antagonists to treat cachexia
WO2002070511A1 (en) 2001-03-02 2002-09-12 Bristol-Myers Squibb Company Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same
US6770645B2 (en) * 2001-03-16 2004-08-03 Pfizer Inc. Pharmaceutically active compounds
CA2453515A1 (en) * 2001-07-11 2003-01-23 Palatin Technologies, Inc. Linear and cyclic melanocortin receptor-specific peptides
US7034004B2 (en) 2002-05-07 2006-04-25 University Of Florida Peptides and methods for the control of obesity
US20040128136A1 (en) * 2002-09-20 2004-07-01 Irani Pourang Polad Internet voice browser
US20060293223A1 (en) * 2003-06-19 2006-12-28 Eli Lilly And Company Patent Division Uses of melanocortin-3 receptor (mc3r) agonist peptides
KR20060014444A (ko) * 2003-06-19 2006-02-15 일라이 릴리 앤드 캄파니 멜라노코르틴 수용체 4 (ｍｃ4) 작용제 및 그의 용도
US7084111B2 (en) 2003-06-23 2006-08-01 University Of Florida Research Foundation, Inc. Melanocortin receptor templates, peptides, and use thereof
WO2005019184A1 (en) * 2003-08-20 2005-03-03 Eli Lilly And Company Compounds, methods and formulations for the oral delivery of a glucagon like peptide (glp)-1 compound or an melanocortin 4 receptor (mc4) agonist peptide
CA2530983C (en) * 2003-08-20 2012-09-25 Eli Lilly And Company Compounds, methods and formulations for the oral delivery of a glucagon like peptide (glp)-1 compound or an melanocortin 4 receptor (mc4) agonist peptide
WO2005040109A1 (en) * 2003-10-22 2005-05-06 Neurocrine Biosciences, Inc. Ligands of melanocortin receptors and compositions and methods related thereto
DE10355559A1 (de) 2003-11-21 2005-06-23 Orthogen Ag Transskin
EP1694348A4 (en) 2003-12-10 2009-07-01 Merck & Co Inc VOLUNTARY INHIBITION OF CONSUMPTION OF ETHANOL USING MELANOCORTIN RECEPTOR 4 RECEPTOR AGONISTS
EP1732586A1 (en) 2004-03-29 2006-12-20 Eli Lilly And Company Uses of melanocortin-4 receptor (mc4r) agonist peptides administered by continunous infusion
JP5449673B2 (ja) 2004-10-08 2014-03-19 クリヌベール、ファーマスーティカルズ、リミテッド 対象者におけるメラニン形成を誘導するための組成物および方法
WO2006073772A1 (en) 2005-01-05 2006-07-13 Eli Lilly And Company Polyethylene glycol linked mc4r or mc3r agonist peptides
WO2006073771A2 (en) 2005-01-05 2006-07-13 Eli Lilly And Company Polyethylene glycol linked mc4r or mc3r agonist peptides
CA2620228C (en) 2005-08-26 2014-12-09 Action Pharma A/S Therapeutically active .alpha.-msh analogues

Also Published As

Publication number Publication date
EP2236151A1 (en) 2010-10-06
ES2386862T3 (es) 2012-09-03
HUE031731T2 (en) 2017-07-28
NZ565217A (en) 2010-03-26
PL2548568T3 (pl) 2018-06-29
HK1149190A1 (en) 2011-09-30
PT3354273T (pt) 2021-06-28
US20110183886A1 (en) 2011-07-28
JP2013253090A (ja) 2013-12-19
CN101257916A (zh) 2008-09-03
US20200095281A1 (en) 2020-03-26
US9458195B2 (en) 2016-10-04
HUE037147T2 (hu) 2018-08-28
RU2380372C2 (ru) 2010-01-27
CA3044795A1 (en) 2007-01-18
CN101257916B (zh) 2013-04-03
EP2548568A3 (en) 2013-07-17
RU2009131092A (ru) 2011-02-20
PT2236151E (pt) 2012-07-02
JP2009500427A (ja) 2009-01-08
EP2286825A2 (en) 2011-02-23
ES2877349T3 (es) 2021-11-16
EP3354273A1 (en) 2018-08-01
CN105837661A (zh) 2016-08-10
EP2548568B1 (en) 2018-01-10
US20180105557A1 (en) 2018-04-19
EP2286825A3 (en) 2011-07-27
AU2006269261B2 (en) 2009-12-17
US8039435B2 (en) 2011-10-18
US9850280B2 (en) 2017-12-26
IL201732A0 (en) 2010-06-16
CN103755786A (zh) 2014-04-30
US20100279922A1 (en) 2010-11-04
EP2236151B1 (en) 2012-05-23
SG163585A1 (en) 2010-08-30
CN101676298A (zh) 2010-03-24
EP2548568A2 (en) 2013-01-23
JP2015232003A (ja) 2015-12-24
NL301150I2 (nl) 2022-11-24
KR101232201B1 (ko) 2013-02-12
EP3925614A3 (en) 2022-03-23
RU2439079C2 (ru) 2012-01-10
DK2286825T3 (en) 2017-01-09
PL2236151T3 (pl) 2012-10-31
HUE055154T2 (hu) 2021-11-29
WO2007008704A2 (en) 2007-01-18
KR20080049711A (ko) 2008-06-04
IL246392A (en) 2017-07-31
ES2663916T3 (es) 2018-04-17
EP2286825B1 (en) 2016-09-28
HUS2100054I1 (hu) 2021-12-28
CA3228910A1 (en) 2007-01-18
DK3354273T3 (da) 2021-06-28
JP2010090130A (ja) 2010-04-22
KR20100016120A (ko) 2010-02-12
HK1258965A1 (zh) 2019-11-22
DK2236151T3 (da) 2012-07-09
JP5965520B2 (ja) 2016-08-03
PT2548568T (pt) 2018-03-21
FR21C1060I2 (fr) 2022-12-02
NZ580806A (en) 2012-07-27
DK2548568T3 (en) 2018-03-12
KR100997177B1 (ko) 2010-11-29
JP4734411B2 (ja) 2011-07-27
FR21C1060I1 (fr) 2022-01-21
CA2614615A1 (en) 2007-01-18
IL188545A0 (en) 2008-04-13
US20220127305A1 (en) 2022-04-28
ES2604328T3 (es) 2017-03-06
US20160368962A1 (en) 2016-12-22
EP1915167A2 (en) 2008-04-30
CA2793119C (en) 2019-07-23
US20170240595A1 (en) 2017-08-24
US20180305406A1 (en) 2018-10-25
EP3925614A2 (en) 2021-12-22
CN103755786B (zh) 2016-05-11
CA2614615C (en) 2012-10-16
AU2006269261A1 (en) 2007-01-18
SI3354273T1 (sl) 2021-10-29
IL188545A (en) 2011-08-31
CA2793119A1 (en) 2007-01-18
PL2286825T3 (pl) 2017-06-30
AU2009230799B2 (en) 2012-02-09
EP1915167A4 (en) 2010-04-07
EP3354273B1 (en) 2021-03-24
AU2009230799A1 (en) 2009-11-19
JP5889513B2 (ja) 2016-03-22
RU2008104803A (ru) 2009-08-20
PL3354273T3 (pl) 2021-10-11
NL301150I1 (pt) 2021-12-08
IL201732A (en) 2016-07-31
WO2007008704A3 (en) 2007-10-11

Similar Documents

Publication Publication Date Title
HUS2100054I1 (hu) Melanokortin receptor ligandumok
IL188544A0 (en) Ligands of melanocortin receptors
EP1872421A4 (en) MEANS FOR CONNECTING TERMINALS
GB0505941D0 (en) Human-to-mobile interfaces
ZA200801743B (en) Intermediate bracket
IL189265A0 (en) Ferrocene-diphosphine ligands
EP1869271A4 (en) SUPPORT
GB0624987D0 (en) Novel aminoguanidines as melanocortin receptor ligands
GB0613762D0 (en) Slabline structure
GB0516946D0 (en) Receptor
GB0602684D0 (en) Bracket
GB2418125B (en) Saddle cover
GB0521122D0 (en) Mat
GB0522077D0 (en) Receptor
GB0510253D0 (en) Receptor
GB0522394D0 (en) Receptor
GB0522484D0 (en) Receptor
GB0524953D0 (en) Bracket
AU305163S (en) Bracket
AU305162S (en) Bracket
AU307179S (en) Bracket
GB0514990D0 (en) Mats
TWM291769U (en) Ant-slip mat
GB0516849D0 (en) Attachment means
GB0506820D0 (en) Saddles